AbbVie Delivers 400% Returns Beating The S&P 500 by 139%

Market Intelligence Analysis

AI-Powered 70% FREE-ANALYSIS-RULE-BASED-ANALYSIS
Why This Matters

Financial market analysis indicating bearish sentiment based on current trends.

Sentiment
Bearish
AI Confidence
70%
Time Horizon
Short Term
Affected Symbols

Article Context

Note: This is a brief excerpt for context. Click below to read the full article on the original source.

Ten years ago, AbbVie (NYSE:ABBV) was a one-drug story. Humira, the world’s best-selling medicine, threw off the cash that funded everything else. Bears had been warning about its U.S. patent cliff for years, and when biosimilars finally hit in 2023, the drug went into freefall. Humira sales dropped to just $688 million in Q1 2026, ... AbbVie Delivers 400% Returns Beating The S&P 500 by 139%

Continue Reading
Full article on Yahoo Finance
Read Full Article
AI Breakdown

Summary

Financial market analysis indicating bearish sentiment based on current trends.

Time Horizon

Short Term

Original article published by Yahoo Finance on June 3, 2026.
Analysis and insights provided by AnalystMarkets AI.